ଇଲାସେଷ୍ଟ୍ରାଣ୍ଟ

ଇଲାସେଷ୍ଟ୍ରାଣ୍ଟ
Clinical data
Pronunciation	/ˌɛləˈsɛstrənt/; EL-ə-SES-trənt
Trade names	Orserdu
Synonyms	RAD-1901; ER-306323
data	US DailyMed: Elacestrant;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Bioavailability	~10%
Protein binding	>99%
Metabolism	Liver (major: CYP3A4, minor: CYP2A6, CYP2C9)
Elimination half-life	30–50 hours
Excretion	Feces (82%), urine (7.5%)
Identifiers
	IUPAC name (6R)-6-{2-[Ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol;
ECHA InfoCard	100.312.890
Chemical and physical data
Formula	C30H38N2O2
Molar mass	୪୫୮.୬୫ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)C3CCC4=C(C3)C=CC(=C4)O;
	InChI InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1; Key:SIFNOOUKXBRGGB-AREMUKBSSA-N;

ଇଲାସେଷ୍ଟ୍ରାଣ୍ଟ (ଇଂରାଜୀ ଭାଷାରେ Elacestrant), ଓରସେର୍ଡୁ ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ସ୍ତନ କର୍କଟ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ ।^[୧] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ଇଆର-ଯୁକ୍ତାତ୍ମକ, ଏଚଇଆର୨- ବିଯୁକ୍ତାତ୍ମକ ଓ ଇଏସଆର୧- ପରିବର୍ତ୍ତିତ ଉନ୍ନତ ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ଯାହା ଅନ୍ୟ ଚିକିତ୍ସାରେ ବିଫଳ ହୁଏ ।^[୧] ଋତୁବନ୍ଦ ପରେ କିମ୍ବା ପୁରୁଷମାନଙ୍କଠାରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।^[୧] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅସ୍ଥି-ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା, ଅଇ, ରକ୍ତ କୋଲେଷ୍ଟେରୋଲ ବୃଦ୍ଧି, ଯକୃତ ଏନଜାଇମ୍ ବୃଦ୍ଧି, ରକ୍ତର ଟ୍ରାଇଗ୍ଲିସେରାଇଡ୍ ବୃଦ୍ଧି, ଥକ୍କାପଣ, ହେମୋଗ୍ଲୋବିନ୍ ହ୍ରାସ, ସୋଡିଅମ୍ ହ୍ରାସ, ବୃକ୍‌କ ସମସ୍ୟା, ତରଳ ଝାଡ଼ା, ମୁଣ୍ଡବିନ୍ଧା, କୋଷ୍ଠକାଠିନ୍ୟ, ପେଟ ଯନ୍ତ୍ରଣା, ଗରମ ଫ୍ଲାସ୍ ଏବଂ ପେଟ ଖରାପ ହୋଇପାରେ ।^[୧] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି କରିପାରେ ।^[୧] ଏହା ସିଯାଇପି୩ଏ୪କୁ ପ୍ରଭାବିତ କରୁଥିବା ଔଷଧ ସହିତ ପ୍ରତିକ୍ରିୟା କରିପାରେ ।^[୧] ଇଷ୍ଟ୍ରୋଜେନ୍ସର କାର୍ଯ୍ୟକୁ ଅବରୋଧ କରି ଏହା କାମ କରେ ।^[୧]

୨୦୨୩ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଇଲାସେଷ୍ଟ୍ରାଣ୍ଟ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ଚିକିତ୍ସାରେ ମାସକୁ ପ୍ରାୟ ୨୨,୫୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୁଏ ।^[୩]

ଆଧାର

↑ ^୧.୦୦ ^୧.୦୧ ^୧.୦୨ ^୧.୦୩ ^୧.୦୪ ^୧.୦୫ ^୧.୦୬ ^୧.୦୭ ^୧.୦୮ ^୧.୦୯ ^୧.୧୦ ^୧.୧୧ ^୧.୧୨ ^୧.୧୩ ^୧.୧୪ "Orserdu- elacestrant tablet, film coated". DailyMed. 8 February 2023. Archived from the original on 11 February 2023. Retrieved 11 February 2023.
↑ "FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer". U.S. Food and Drug Administration (FDA). 27 January 2023. Archived from the original on 2 February 2023. Retrieved 1 February 2023. This article incorporates text from this source, which is in the public domain.
↑ "Orserdu Prices, Coupons, Copay & Patient Assistance". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 1 July 2023. Retrieved 14 May 2023.

[PI2023-1] ୧.୦୦ ^୧.୦୧ ^୧.୦୨ ^୧.୦୩ ^୧.୦୪ ^୧.୦୫ ^୧.୦୬ ^୧.୦୭ ^୧.୦୮ ^୧.୦୯ ^୧.୧୦ ^୧.୧୧ ^୧.୧୨ ^୧.୧୩ ^୧.୧୪ "Orserdu- elacestrant tablet, film coated". DailyMed. 8 February 2023. Archived from the original on 11 February 2023. Retrieved 11 February 2023.

[FDA_20230127-2] "FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer". U.S. Food and Drug Administration (FDA). 27 January 2023. Archived from the original on 2 February 2023. Retrieved 1 February 2023. This article incorporates text from this source, which is in the public domain.

[3] "Orserdu Prices, Coupons, Copay & Patient Assistance". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 1 July 2023. Retrieved 14 May 2023.

[୧]

[୨]

[୩]

Clinical data

Pronunciation	/ˌɛləˈsɛstrənt/ EL-ə-SES-trənt
Trade names	Orserdu
Synonyms	RAD-1901; ER-306323
data	US DailyMed: Elacestrant
Routes of administration	By mouth
Legal status
Legal status	US: ℞-only ^[୧]^[୨]
Pharmacokinetic data
Bioavailability	~10%^[୧]
Protein binding	>99%^[୧]
Metabolism	Liver (major: CYP3A4, minor: CYP2A6, CYP2C9)^[୧]
Elimination half-life	30–50 hours^[୧]
Excretion	Feces (82%), urine (7.5%)^[୧]
Identifiers
IUPAC name (6R)-6-{2-[Ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol
ECHA InfoCard	100.312.890
Chemical and physical data
Formula	C₃₀H₃₈N₂O₂
Molar mass	୪୫୮.୬୫ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)C3CCC4=C(C3)C=CC(=C4)O
InChI InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1 Key:SIFNOOUKXBRGGB-AREMUKBSSA-N